Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;21(2):143-9.
doi: 10.1097/BOR.0b013e328325bd94.

Update on emerging urate-lowering therapies

Saima Chohan  1 , Michael A Becker
Affiliations
Review

Update on emerging urate-lowering therapies

Saima Chohan et al. Curr Opin Rheumatol. 2009 Mar.

Erratum in

  • Curr Opin Rheumatol. 2010 Jan;22(1):106

Abstract

Purpose of review: To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development.

Recent findings: Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase.

Summary: There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.

PubMed Disclaimer